Coherus Oncology, Inc.CHRSNASDAQ
Loading
SG&A Expenses Over TimeContracting
Percentile Rank54
3Y CAGR-20.8%
5Y CAGR-6.7%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-20.8%/yr
vs +20.5%/yr prior
5Y CAGR
-6.7%/yr
Recent deceleration
Acceleration
-41.3pp
Decelerating
Percentile
P54
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$98.50M-34.5%
2024$150.44M-19.0%
2023$185.62M-6.5%
2022$198.48M+17.0%
2021$169.71M+22.0%
2020$139.08M+1.5%
2019$137.04M+45.5%
2018$94.18M+32.1%
2017$71.30M+38.2%
2016$51.60M-